Trinomab
Developer of antibody biopharmaceuticals and provider of related research services.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD563—844m (Dealroom.co estimates Nov 2022.)
Zhuhai Guangdong (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | CNY300m | Seed | |
CNY450m | Series A | ||
* | CNY750m | Late VC | |
| Total Funding | CAD281m | ||